| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BBC3, JFY1, JFY-1, |
| Entrez GeneID | 27113; |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
+ +
以下是关于PUMA抗体的3篇参考文献，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*PUMA, a novel pro-apoptotic gene, is induced by p53*
**作者**：K. Nakano, K.H. Vousden (2001)
**摘要**：该研究首次报道了PUMA作为p53依赖的凋亡通路关键介质。通过Northern blot和Western blot分析，使用特异性PUMA抗体验证其在DNA损伤后的表达上调，并证明其通过激活线粒体途径诱导细胞凋亡。
---
2. **文献名称**：*PUMA mediates the apoptotic response to p53 in colorectal cancer cells*
**作者**：J. Yu, L. Zhang (2001)
**摘要**：研究利用PUMA抗体检测结直肠癌细胞中PUMA蛋白水平，发现p53通过转录激活PUMA触发凋亡。抗体特异性验证显示，PUMA缺失型细胞在放疗后凋亡率显著降低，支持其在肿瘤抑制中的作用。
---
3. **文献名称**：*Differential roles of PUMA and NOXA in ischemic brain injury*
**作者**：W. Cheng, M. Yan (2005)
**摘要**：通过免疫组化和Western blot(使用PUMA抗体)，研究比较了缺血再灌注模型中PUMA与NOXA的表达差异。结果显示，PUMA敲除显著减少神经元凋亡，而NOXA缺失影响较小，提示PUMA在缺血损伤中的主导作用。
---
4. **文献名称**：*Antibody-based detection of PUMA in chemoresistance studies*
**作者**：C. Reimertz, A. Villunger (2003)
**摘要**：该文献开发了高特异性单克隆PUMA抗体，并验证其在多种细胞系中的适用性。研究发现，化疗药物处理后PUMA表达与耐药性相关，抗体检测为评估肿瘤细胞凋亡敏感性提供了工具。
---
**说明**：以上文献涵盖PUMA抗体的基础机制研究(如p53通路)、疾病模型应用(如缺血损伤、癌症)及抗体开发验证。实际引用时建议核对期刊名称、卷号及具体年份。
The Puma (p53 upregulated modulator of apoptosis) antibody is a critical tool in apoptosis research, targeting the Puma protein, a pro-apoptotic member of the Bcl-2 family. Discovered in 2001. Puma is transcriptionally activated by p53 under stress conditions, such as DNA damage or oncogene activation, and plays a pivotal role in initiating mitochondrial apoptosis by binding to anti-apoptotic Bcl-2 proteins. Its broad involvement in cell death pathways makes it a focus in cancer, neurodegeneration, and autoimmune disease studies.
Puma antibodies are designed to detect and quantify endogenous Puma protein levels in various experimental models. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to explore Puma's regulation, interactions, and therapeutic potential. For instance, researchers employ Puma antibodies to assess its upregulation during chemotherapy-induced apoptosis or its suppression in drug-resistant cancers. Specificity and sensitivity are key considerations, as Puma shares structural homology with other BH3-only proteins. Recent advances in monoclonal antibody development have improved target selectivity, enabling precise mechanistic studies. The availability of Puma antibodies continues to drive discoveries in cell fate decisions and therapeutic strategies targeting apoptotic pathways.
×
